VIRP Virbac SA

Virbac : Public release of Virbac Annual Report at 31 December 2024

Virbac : Public release of Virbac Annual Report at 31 December 2024

The Group released and filed its 2024 Annual Report with the French “Autorité des marchés financiers”, at the ESEF Format.

Additionally, the report is attached at the PDF format.

The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports” at the ESEF format and PDF format.

Attachments



EN
28/04/2025

Underlying

VIRPVirbac SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Virbac SA

Anthony Dick ... (+3)
  • Anthony Dick
  • Marc Lavaud
  • Michael Foundoukidis
CON CONTINENTAL AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
RNO RENAULT SA
APAML APERAM SA
VOLV B VOLVO AB CLASS B
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
KCO KLOECKNER & CO SE
VIRP VIRBAC SA
JCQ JACQUET METALS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
FR VALEO SE
VOW3 VOLKSWAGEN AG PREF
CIE CIE AUTOMOTIVE S.A.
RACE FERRARI NV
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
PIRC PIRELLI & C. S.P.A.
GEST GESTAMP AUTOMOCION S.A.
8TRA TRATON SE
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
DTG DAIMLER TRUCK
IVG IVECO GROUP
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
NCH2 THYSSENKRUPP NUCERA AG & CO.
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
12/17/25 December 17, 2025 1 FR
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
12/17/25 December 17, 2025 1 EN
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
12/17/25 December 17, 2025 1 FR
 PRESS RELEASE
Free
VIRP VIRBAC SA

VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm

VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.We are delighted to announce the acquisition of an innovative drug from Norbrook to stabilize feline hyperthyroidism. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) b...

December 16, 2025 1 EN
 PRESS RELEASE
Free
VIRP VIRBAC SA

VIRBAC: Hyperthyroïdie féline : Virbac acquiert Thyronorm

VIRBAC: Hyperthyroïdie féline : Virbac acquiert Thyronorm Cette acquisition apporte à Virbac un produit de spécialité de premier plan, sur un segment en croissance, pour améliorer la qualité de vie des chats âgés.Nous sommes ravis d'annoncer l'acquisition auprès de Norbrook d’un médicament innovant pour stabiliser l'hyperthyroïdie féline. Virbac assurera la distribution directe de ce traitement sous la marque Thyronorm au Royaume-Uni, en Australie et Nouvelle-Zélande ainsi qu’aux États-Unis sous la marque Felanorm,. En Europe, la distribution restera gérée par Boehringer Ingelheim et Elanco...

December 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch